NEW YORK (GenomeWeb) – CombiMatrix this week introduced CombiPGS, a new preimplantantion genetic screening test for women undergoing in vitro fertilization.
Run using bacterial artificial chromosome arrays from within its Irvine, Calif.-based services laboratory, CombiPGS allows CombiMatrix to enter a "lucrative, cash-pay market," CEO Mark McDonough said in a statement.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
